Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.71 |
| ▸ | CA2 | P00918 | 13/20 | 0.71 |
| ▸ | CA4 | P22748 | 13/20 | 0.71 |
| ▸ | CA6 | P23280 | 13/20 | 0.71 |
| ▸ | PARP1 | P09874 | 3/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8946292 | 0.88 | CA1 (0.71) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL2296063 | 0.83 | CA1 (0.83) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL2298597 | 0.82 | CA1 (1.00) | CA1CA2CA4CA6CCNB2 | |
| SCHEMBL29370925 | 0.82 | CA1 (1.00) | CA1CA2CA4CA6CCNB2 | |
| SCHEMBL9531089 | 0.82 | CA1 (0.71) | CA1CA2CA4CA6CCNB2 | |
| SCHEMBL12382594 | 0.82 | CA1 (0.69) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL12382617 | 0.78 | CA1 (0.58) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL2294178 | 0.78 | CA1 (0.73) | CA1CA2CA4CA6CCNB2 | |
| SCHEMBL28218318 | 0.76 | CA1 (0.49) | CA1CA2CA4CA6PARP1 | |
| SCHEMBL2296790 | 0.75 | CA1 (0.68) | CA1CA2CA4CA6PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703936-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703936-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703936-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140045207-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045207-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045207-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | disclosed |
| US-8519122-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519122-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519122-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-25 | — | — | US | disclosed |
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-25 | — | — | US | disclosed |
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | PTMS, APEX1, ALG1 | CA1 517/4885CA2 1721/4885CA4 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.